TBI-223

Class: Oxazolidinone

Spectrum of activity:	Gram-positive
Details of activity:	Active against Staphylococcus aureus (first report) and Mycobacterium tuberculosis
Description:	Synthetic compound; may replace linezolid in BPaL regimen to treat drug-susceptible and -resistant TB
Institute where first reported:	TB Alliance (New York, NY, USA) and the Institute of Materia Medica (Shanghai, People’s Republic of China)
Year first mentioned:	2019
Highest developmental phase:	Phase 1 (NCT04865536)
Development status:	Active (as of 2023)

Chemical structure(s):
Canonical SMILES:	COC(=O)NC[C@H]1CN(C2=CC=C(C(=C2)F)N3CC4(C3)COC4)C(=O)O1
Isomeric SMILES:	COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
InChI:	InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
InChI Key:	ZNBRXLSWXJKKLJ-LBPRGKRZSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/126494519

External links:
Guide to Pharmacology:	TBI-223
Main Source:	https://journals.asm.org/doi/10.1128/aac.00035-23
Citation:	https://journals.asm.org/doi/full/10.1128/spectrum.02451-21?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org